Randomized pharmacodynamic and pharmacogenetic trial of dronabinol effects on colon transit in irritable bowel syndrome-diarrhea

B. S. Wong, Michael Camilleri, D. Eckert, P. Carlson, M. Ryks, D. Burton, A. R. Zinsmeister

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Background Genetic variation in endocannabinoid metabolism is associated with colonic transit in irritable bowel syndrome (IBS) with diarrhea (IBS-D). The nonselective cannabinoid (CB) receptor agonist, dronabinol (DRO), reduced fasting colonic motility in nonconstipated IBS. FAAH and CNR1 variants influenced DRO's effects on colonic motility. Our aims were: (i) to compare dose-related effects of DRO to placebo (PLA) on gut transit in IBS-D, and (ii) to examine influence of genetic variations in CB mechanisms on DRO's transit effects. Methods Thirty-six IBS-D volunteers were randomized (double-blind, concealed allocation) to twice per day PLA (n=13), DRO 2.5mg (n=10), or DRO 5mg (n=13) for 2days. We assessed gastric, small bowel, and colonic transit by validated radioscintigraphy and genotyped the single nucleotide polymorphisms CNR1 rs806378 and FAAH rs324420. Data analysis utilized a dominant genetic model. Key Results Overall treatment effects of DRO on gastric, small bowel, or colonic transit were not detected. CNR1 rs806378 CT/TT was associated with a modest delay in colonic transit at 24h compared with CC (P=0.13 for differential treatment effects on postminus pretreatment changes in colonic transit by genotype). No significant interaction of treatment with FAAH rs324420 was detected. Conclusions & Inferences Overall, DRO 2.5 or 5mg twice per day for 2days had no effect on gut transit in IBS-D. There appears to be a treatment-by-genotype effect, whereby DRO preferentially delays colonic transit in those with the CNR1 rs806378 CT/TT genotypes. Further study of CB pharmacogenetics may help identify a subset of IBS-D patients most likely to benefit from CB agonist therapy.

Original languageEnglish (US)
JournalNeurogastroenterology and Motility
Volume24
Issue number4
DOIs
StatePublished - Apr 2012

Fingerprint

Dronabinol
Irritable Bowel Syndrome
Pharmacogenetics
Diarrhea
Colon
Cannabinoid Receptor Agonists
Cannabinoids
Genotype
Stomach
Placebos
Therapeutics
Endocannabinoids
Genetic Models
Single Nucleotide Polymorphism
Volunteers
Fasting

Keywords

  • Anandamide
  • Cannabinoid
  • Fatty acid amide hydrolase
  • Gastric
  • Motility
  • Nonselective
  • Receptor
  • Small bowel

ASJC Scopus subject areas

  • Endocrine and Autonomic Systems
  • Gastroenterology
  • Physiology

Cite this

Randomized pharmacodynamic and pharmacogenetic trial of dronabinol effects on colon transit in irritable bowel syndrome-diarrhea. / Wong, B. S.; Camilleri, Michael; Eckert, D.; Carlson, P.; Ryks, M.; Burton, D.; Zinsmeister, A. R.

In: Neurogastroenterology and Motility, Vol. 24, No. 4, 04.2012.

Research output: Contribution to journalArticle

@article{4aa934d16764497bbbc6ed84b054ae8d,
title = "Randomized pharmacodynamic and pharmacogenetic trial of dronabinol effects on colon transit in irritable bowel syndrome-diarrhea",
abstract = "Background Genetic variation in endocannabinoid metabolism is associated with colonic transit in irritable bowel syndrome (IBS) with diarrhea (IBS-D). The nonselective cannabinoid (CB) receptor agonist, dronabinol (DRO), reduced fasting colonic motility in nonconstipated IBS. FAAH and CNR1 variants influenced DRO's effects on colonic motility. Our aims were: (i) to compare dose-related effects of DRO to placebo (PLA) on gut transit in IBS-D, and (ii) to examine influence of genetic variations in CB mechanisms on DRO's transit effects. Methods Thirty-six IBS-D volunteers were randomized (double-blind, concealed allocation) to twice per day PLA (n=13), DRO 2.5mg (n=10), or DRO 5mg (n=13) for 2days. We assessed gastric, small bowel, and colonic transit by validated radioscintigraphy and genotyped the single nucleotide polymorphisms CNR1 rs806378 and FAAH rs324420. Data analysis utilized a dominant genetic model. Key Results Overall treatment effects of DRO on gastric, small bowel, or colonic transit were not detected. CNR1 rs806378 CT/TT was associated with a modest delay in colonic transit at 24h compared with CC (P=0.13 for differential treatment effects on postminus pretreatment changes in colonic transit by genotype). No significant interaction of treatment with FAAH rs324420 was detected. Conclusions & Inferences Overall, DRO 2.5 or 5mg twice per day for 2days had no effect on gut transit in IBS-D. There appears to be a treatment-by-genotype effect, whereby DRO preferentially delays colonic transit in those with the CNR1 rs806378 CT/TT genotypes. Further study of CB pharmacogenetics may help identify a subset of IBS-D patients most likely to benefit from CB agonist therapy.",
keywords = "Anandamide, Cannabinoid, Fatty acid amide hydrolase, Gastric, Motility, Nonselective, Receptor, Small bowel",
author = "Wong, {B. S.} and Michael Camilleri and D. Eckert and P. Carlson and M. Ryks and D. Burton and Zinsmeister, {A. R.}",
year = "2012",
month = "4",
doi = "10.1111/j.1365-2982.2011.01874.x",
language = "English (US)",
volume = "24",
journal = "Neurogastroenterology and Motility",
issn = "1350-1925",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Randomized pharmacodynamic and pharmacogenetic trial of dronabinol effects on colon transit in irritable bowel syndrome-diarrhea

AU - Wong, B. S.

AU - Camilleri, Michael

AU - Eckert, D.

AU - Carlson, P.

AU - Ryks, M.

AU - Burton, D.

AU - Zinsmeister, A. R.

PY - 2012/4

Y1 - 2012/4

N2 - Background Genetic variation in endocannabinoid metabolism is associated with colonic transit in irritable bowel syndrome (IBS) with diarrhea (IBS-D). The nonselective cannabinoid (CB) receptor agonist, dronabinol (DRO), reduced fasting colonic motility in nonconstipated IBS. FAAH and CNR1 variants influenced DRO's effects on colonic motility. Our aims were: (i) to compare dose-related effects of DRO to placebo (PLA) on gut transit in IBS-D, and (ii) to examine influence of genetic variations in CB mechanisms on DRO's transit effects. Methods Thirty-six IBS-D volunteers were randomized (double-blind, concealed allocation) to twice per day PLA (n=13), DRO 2.5mg (n=10), or DRO 5mg (n=13) for 2days. We assessed gastric, small bowel, and colonic transit by validated radioscintigraphy and genotyped the single nucleotide polymorphisms CNR1 rs806378 and FAAH rs324420. Data analysis utilized a dominant genetic model. Key Results Overall treatment effects of DRO on gastric, small bowel, or colonic transit were not detected. CNR1 rs806378 CT/TT was associated with a modest delay in colonic transit at 24h compared with CC (P=0.13 for differential treatment effects on postminus pretreatment changes in colonic transit by genotype). No significant interaction of treatment with FAAH rs324420 was detected. Conclusions & Inferences Overall, DRO 2.5 or 5mg twice per day for 2days had no effect on gut transit in IBS-D. There appears to be a treatment-by-genotype effect, whereby DRO preferentially delays colonic transit in those with the CNR1 rs806378 CT/TT genotypes. Further study of CB pharmacogenetics may help identify a subset of IBS-D patients most likely to benefit from CB agonist therapy.

AB - Background Genetic variation in endocannabinoid metabolism is associated with colonic transit in irritable bowel syndrome (IBS) with diarrhea (IBS-D). The nonselective cannabinoid (CB) receptor agonist, dronabinol (DRO), reduced fasting colonic motility in nonconstipated IBS. FAAH and CNR1 variants influenced DRO's effects on colonic motility. Our aims were: (i) to compare dose-related effects of DRO to placebo (PLA) on gut transit in IBS-D, and (ii) to examine influence of genetic variations in CB mechanisms on DRO's transit effects. Methods Thirty-six IBS-D volunteers were randomized (double-blind, concealed allocation) to twice per day PLA (n=13), DRO 2.5mg (n=10), or DRO 5mg (n=13) for 2days. We assessed gastric, small bowel, and colonic transit by validated radioscintigraphy and genotyped the single nucleotide polymorphisms CNR1 rs806378 and FAAH rs324420. Data analysis utilized a dominant genetic model. Key Results Overall treatment effects of DRO on gastric, small bowel, or colonic transit were not detected. CNR1 rs806378 CT/TT was associated with a modest delay in colonic transit at 24h compared with CC (P=0.13 for differential treatment effects on postminus pretreatment changes in colonic transit by genotype). No significant interaction of treatment with FAAH rs324420 was detected. Conclusions & Inferences Overall, DRO 2.5 or 5mg twice per day for 2days had no effect on gut transit in IBS-D. There appears to be a treatment-by-genotype effect, whereby DRO preferentially delays colonic transit in those with the CNR1 rs806378 CT/TT genotypes. Further study of CB pharmacogenetics may help identify a subset of IBS-D patients most likely to benefit from CB agonist therapy.

KW - Anandamide

KW - Cannabinoid

KW - Fatty acid amide hydrolase

KW - Gastric

KW - Motility

KW - Nonselective

KW - Receptor

KW - Small bowel

UR - http://www.scopus.com/inward/record.url?scp=84858297594&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858297594&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2982.2011.01874.x

DO - 10.1111/j.1365-2982.2011.01874.x

M3 - Article

C2 - 22288893

AN - SCOPUS:84858297594

VL - 24

JO - Neurogastroenterology and Motility

JF - Neurogastroenterology and Motility

SN - 1350-1925

IS - 4

ER -